《公司業績》合生創展(00754.HK)全年核心利潤跌63% 末期息15仙兼派紅股
合生創展集團(00754.HK)公佈截至去年12月底止全年業績,營業額307.34億元,按年跌10.6%。純利97.59億元,按年跌28.4%;每股盈利3.71仙。派末期息15仙。公司同時公佈,每持有10股現有股份發行1股新股之基準發行紅股。
扣除除稅後投資物業重估收益淨額78.38億元,按年增12.7倍;核心利潤爲47.56億元,按年跌62.8%,主要由於投資板塊虧損所致。
2021年銷售及預售合約出售的物業總額達422.99億元,按年增18%。於去年12月底,集團之負債對資產比率爲67%,按年持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.